Impact of extending direct antiviral agents (DAA) availability in France: an observational cohort study (2015-2019) of data from French administrative healthcare databases (SNDS).
Summary: Background: Direct antiviral agents (DAAs) became available in France in 2014 for the treatment of chronic hepatitis C (CHC) in patients with severe fibrosis (prioritized access); in 2017, DAAs became available to all CHC patients (universal access). We evaluated the impact of extending DAA...
Saved in:
Main Authors: | Stanislas Pol (Author), Fayssoil Fouad (Author), Magali Lemaitre (Author), Ingrid Rodriguez (Author), Olivier Lada (Author), Pascaline Rabiega (Author), Elias Benabadji (Author), Françoise Roudot-Thoraval (Author) |
---|---|
Format: | Book |
Published: |
Elsevier,
2022-02-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Management of Hepatitis C Infection with Direct Action Antiviral Drugs (DAA)**
by: Roberto Focaccia, et al.
Published: (2015) -
DAA - directly acting antivirals - as a new, more efficient solution of the chronic hepatitis C treatment and theirs various application.
by: Kamila Abram, et al.
Published: (2023) -
Vertical transmission of hepatitis C: towards universal antenatal screening in the era of new direct acting antivirals (DAAs)? Short review and analysis of the situation in Switzerland
by: Karoline Aebi-Popp, et al.
Published: (2016) -
P29 Treating hepatitis C virus infection (HCV) with direct acting antivirals (DAAs) through the existing infrastructure of opioid agonist therapy (OAT)
by: J. Keats, et al.
Published: (2017) -
Anti-HCV DAA are needed whatever liver fibrosis is. The cons
by: Pablo Barreiro
Published: (2016)